Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT ID: NCT02960646
Last Updated: 2023-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
11 participants
INTERVENTIONAL
2017-01-18
2023-02-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
NCT00080925
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02566304
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004904
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00006042
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
NCT01760655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the safety of a modified peripheral blood (PB) graft for haploidentical transplantation, obtained by using depletion of naive, cluster of differentiation (CD)45RA+ T cells.
SECONDARY OBJECTIVES:
I. To estimate the proportion of patients with engraftment/graft failure. II. To determine the day 100 and 6 month non-relapse mortality (NRM). III. To estimate the cumulative incidence of grade 2-4 and 3-4 acute graft versus (vs.) host disease (aGVHD).
IV. To assess the rate of chronic GVHD within the first year post transplantation.
V. To assess immune reconstitution and the incidence of infectious episodes. VI. To assess disease response, disease-free survival (DFS) and overall survival (OS) after transplantation.
VII. To compare results with a retrospective cohort of patients treated with bone marrow graft on protocol 2009-0266.
OUTLINE:
Patients receive melphalan intravenously (IV) over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo total-body irradiation (TBI) on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and orally (PO) for at least 4 months. Beginning on day 7, patients receive filgrastim subcutaneously (SC) daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
After completion of study treatment, patients are followed up periodically.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (peripheral blood stem cell transplantation)
Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
Cyclophosphamide
Given IV
Filgrastim
Given SC
Fludarabine Phosphate
Given IV
Laboratory Biomarker Analysis
Correlative studies
Melphalan
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo CD45RA depleted peripheral blood stem cell transplantation
Rituximab
Given IV
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
Given IV
Filgrastim
Given SC
Fludarabine Phosphate
Given IV
Laboratory Biomarker Analysis
Correlative studies
Melphalan
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo CD45RA depleted peripheral blood stem cell transplantation
Rituximab
Given IV
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the following
* Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; in second or greater morphologic remission; persistent minimal residual disease
* Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent detectable minimal residual disease (MRD), or with high-risk features defined as: greater than 1 cycle of induction therapy required to achieve remission; preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3 mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8, complex (\> 3 abnormalities)
* Patients with AML must have less than 10% bone marrow blasts and \< 100/mcL absolute peripheral blood blast count
* Patients with AML in CR2, subsequent CR or with active disease at transplant (\< 10% bone marrow blasts)
* MDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher, therapy-related MDS or chronic myelomonocytic leukemia (CMML)
* Aplastic anemia with absolute neutrophil count (ANC) \< 1,000 and transfusion dependent after failed immunosuppression therapy
* Chronic myeloid leukemia (CML) \>= 1st chronic phase, after failed \>=2 lines of tyrosine kinase inhibitors; patients who progressed to blast phase must be in morphologic remission at transplant
* Relapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)
* Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with \< 25% involvement by CLL/SLL cells
* Patients with lymphoblastic lymphoma in remission or after partial response to chemotherapy
* Patients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14) or t(14;16) or hypodiploidy, with advanced disease (stage \>= 2) and /or relapsed after autologous stem cell transplant
* Zubrod performance status 0-1 or Karnofsky performance status \> 70%; patients \> 50 years will have to have a Sorror Comorbidity Index =\< 3
* Available haploidentical donor willing and eligible to undergo a peripheral blood collection
* Left ventricular ejection fraction (LVEF) \> 40%
* Bilirubin =\< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =\< 200 IU/ml for adults; conjugated (direct) bilirubin \< 2 x upper limit of normal
* Serum creatinine clearance \>= 50 ml/min (calculated with Cockcroft-Gault formula)
* Diffusing capacity for carbon monoxide (DLCO) \>= 45% predicted corrected for hemoglobin
* Patient or patient's legal representative must provide written informed consent
Exclusion Criteria
* Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
* Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis
* Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months
* History of another primary malignancy that has not been in remission for at least 3 years; (the following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ \[stage 0\], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)
* Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
* Inability to comply with medical therapy or follow-up
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samer Srour
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-01915
Identifier Type: REGISTRY
Identifier Source: secondary_id
2014-0738
Identifier Type: OTHER
Identifier Source: secondary_id
2014-0738
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.